NCT01448928 - Zevalin Post-marketing Surveillance in Japan | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Non-Hodgkin's Lymphoma (NHL)

Interventions

DRUG

[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.

Trial Locations (1)

Multiple Locations